Thus, it would be interesting to determine whether inhibition of Rho/ROCK-actomyosin-YAP/TAZ signaling and fibrolytic treatment may promote cardiac reprogramming in vivo and improve cardiac function after MI. This evidence concerns the gene WWTR1 and myocardial infarction.